Adocia Share Holder Equity 2016-2023 | ADOCY

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Adocia share holder equity from 2016 to 2023. Share holder equity can be defined as the sum of preferred and common equity items

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Adocia share holder equity from 2016 to 2023. Share holder equity can be defined as the sum of preferred and common equity items

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$171.8B
Vertex Pharmaceuticals (VRTX)	$117.5B
Regeneron Pharmaceuticals (REGN)	$111.6B
Bristol Myers Squibb (BMY)	$109.4B
Gilead Sciences (GILD)	$105.3B
CSL (CSLLY)	$95.7B
GSK (GSK)	$80.5B
Alnylam Pharmaceuticals (ALNY)	$34.4B
Argenex SE (ARGX)	$31.7B
BioNTech SE (BNTX)	$29.2B
Biogen (BIIB)	$27B
BeiGene (BGNE)	$23.9B
Moderna (MRNA)	$23.1B
Illumina (ILMN)	$22.5B
Genmab (GMAB)	$15.5B
BioMarin Pharmaceutical (BMRN)	$13.2B
Incyte (INCY)	$13B
Exact Sciences (EXAS)	$12.6B
Vaxcyte (PCVX)	$12.4B
Insmed (INSM)	$12.4B
Bio-Techne Corp (TECH)	$11.9B
Sarepta Therapeutics (SRPT)	$11.5B
QIAGEN (QGEN)	$9.9B
Bio-Rad Laboratories (BIO.B)	$9.3B
Legend Biotech (LEGN)	$8.9B
Roivant Sciences (ROIV)	$8.4B
Ascendis Pharma (ASND)	$8.3B
Revolution Medicines (RVMD)	$7.9B
Intra-Cellular Therapies (ITCI)	$7.7B
Repligen (RGEN)	$7.7B